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Background/aim: Lead can cause morphological and functional changes in heart, and inflammation and endothelial dysfunction in
vasculature. Endocan, as a novel indicator of endothelial dysfunction, has been used for cardiovascular diseases. This study investigated
the relationship between lead exposure, endocan levels, and diastolic functions.
Materials and methods: A total of 51 lead-exposed workers without a known cardiovascular disease or risk factors and 54 healthy
controls were enrolled. All participants underwent transthoracic echocardiography. Blood lead and serum endocan levels were analyzed.
Results: Baseline demographic and clinical characteristics were found to be similar between groups. Median blood lead (32 vs 1.5 µg/dL,
P < 0.001) and serum endocan levels (67 vs 57.1 pg/mL, P = 0.02) were significantly higher in the lead-exposed group. Serum endocan
level showed a positive correlation with blood lead levels (r = 0.404, P = 0.003) in lead-exposed workers. Serum endocan level was an
independent risk factor for increased E/E’ ratio (β = 0.704, P = 0.002) and left atrial volume index (β = 1.158, P = 0.011) and higher level
of lead in blood was an independent risk factor for increased E wave (β = 8.004, P = 0.022) in lead-exposed workers.
Conclusion: Worsened diastolic functions may be seen in the course of lead exposure. Due to sharing a similar mechanism, a higher
serum level of endocan may be a valuable laboratory clue for impaired diastolic function in this population.
Key words: Lead exposure, endocan, diastolic function

1. Introduction
Lead, a common environmental toxic agent, gives rise
to plenty of cardiovascular diseases including ischemic
heart disease, arterial hypertension, morphological, and
functional changes in heart (1–3). Though its exposure
is considered to be a risk factor for development of
cardiovascular diseases primarily related to arterial
hypertension, it is also capable of causing endothelial
dysfunction (4).
Endocan, also known as endothelial cell-specific
molecule-1, is a soluble proteoglycan expressed by vascular
endothelial cells (5). Previous studies demonstrated that
endocan has a key role in the pathological process of
endothelial dysfunction, and serum endocan level increases
in endothelium-dependent pathologies, inflammatory

diseases, and malignancies (6). Recently, numerous studies
have focused on the relationship between endocan and
cardiovascular diseases (7–9).
The aim of this study was to investigate the relationship
between blood lead levels, serum endocan levels, and
diastolic functions measured by echocardiography in leadexposed workers.
2. Materials and methods
2.1. Study population
In the present cross-sectional study, 64 male workers
occupationally exposed to lead who referred to our clinic
were enrolled. Medical histories and occupational profiles
of the patients were solicited. Physical examination, 12-lead
surface electrocardiogram, laboratory and transthoracic
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echocardiography findings were also evaluated and
recorded. Workers with ischemic heart disease, arterial
hypertension defined as systolic blood pressure of >140
mmHg and diastolic blood pressure of >90 mmHg and/
or taking anti-hypertensive medication, diabetes mellitus,
cigarette smokers, and alcohol consumers were excluded.
In order to eliminate the effects of any conduction
disturbances or arrhythmias on diastolic functions,
subjects suffered from them were also excluded. A total of
13 workers were excluded and of the remaining 51 workers
included, 42 (82.3%) were employed in battery production
and 9 (17.7%) were employed in metal recycling.
Although multiple heavy metal exposure is generally seen
concurrently, the study population was composed of lead
exposure only. The control group included 54 healthy
subjects with no previous history of cardiac disease. All
subjects were males aged older than 18 years. This study
complies with the Declaration of Helsinki, the locally
appointed ethics committee has approved the research
protocol, and informed consent has been obtained from
the subjects.
2.2. Collection and analysis of biological samples
Blood samples were obtained at the end of work shift
and were drawn in 10-mm red-capped tubes that did not
contain gel (BD Vacutainer; Becton Dickinson Medical,
Franklin Lakes, NJ, USA) for analysis of biochemical
parameters. Lead levels were determined in whole
blood samples using inductively coupled plasma-mass
spectrometry (7700 series; Agilent Technologies, Inc.,
Santa Clara, CA, USA). Blood samples were digested using
the microwave-induced acid method. Standard solution of
lead was prepared by dilution of certified standard solutions
(High Purity Standards, Charleston, SC, USA). Two-level
quality control materials were used (Seronorm; Sera AS,
Billingstad, Norway). Lead calibration curve ranged from
0 to 100 μg/dL. Limits of detection and quantification were
0.02 and 0.1 μg/dL, respectively.
2.3. Determination of serum endocan levels
Blood samples for endocan from subjects were also
collected at the end of work shift and transferred to 16
× 100 mm tubes with red caps that did not contain gel
(BD Vacutainer; Becton Dickinson Medical, Franklin
Lakes, NJ, USA). Serum samples were separated after
centrifugation at 1500 g for 10 min and stored at −80
°C until analysis. Serum endocan levels were measured
with commercially available sandwich enzyme-linked
immunosorbent assay (ELISA) kit with high sensitivity
and specificity for detection of human endocan (Boster,
Biological Technology Co. Ltd, Pleasanton, CA, USA).
2.4. Transthoracic echocardiography
Standard echocardiography imaging was performed
according to the recommendations of the American
Society of Echocardiography (10, 11). Left ventricular

dimensions were obtained in parasternal long-axis view.
Left ventricular ejection fraction was calculated according
to the modified biplane Simpson’s rule. In the first instance,
left atrial volume was measured using the biplane arealength method, it was then corrected for body surface area
and redefined as left atrial volume index.
Mitral inflow velocities were measured by pulsed wave
Doppler from apical 4- chamber view positioned at the tips
of mitral leaflets. Peak early filling velocity (E wave), peak
filling velocity during atrial systole (A wave), E/A ratio,
deceleration time of early filling velocity, and isovolumic
relaxation time were calculated. Peak early diastolic tissue
velocity (E’) of mitral annulus was measured from 4chamber view. E/E’ ratio was calculated as E wave divided
by E’.
2.5. Statistical analysis
Statistical analysis was performed using SPSS software
(version 20.0; SPSS Inc., Chicago, IL, USA). Variables with
normal distribution were analyzed using Kolmogorov–
Smirnov test and presented as mean ± SD, while those
without normal distribution were presented as median
with minimum and maximum range. Categorical variables
were presented as number and percentage. Continuous
variables showing normal distribution were compared
with t-test for independent variables, whereas for those
showing no normal distribution, Mann–Whitney U
test was used. Likewise, to test the possible correlation
between variables with and without normal distribution,
Pearson and Spearman correlation analysis were used,
respectively. Stepwise linear regression analysis was used
for multivariate regression analysis. Before this analysis,
logarithmic transformation was applied on variables
without normal distribution.
3. Results
Baseline demographic, clinical and laboratory
characteristics are shown in Table 1. No statistically
significant difference was found between the groups
regarding age, systolic and diastolic blood pressures, and
laboratory parameters. Mean age of the lead-exposed
group was 34.4 ± 7.2 years and that of the control groups
was 33.0 ± 7.9 years. Median blood lead levels [32 µg/dL
(range 13.3–78) vs 1.5 µg/dL (range 0.6–3.1), respectively,
P < 0.001] and serum endocan levels [67 pg/mL (range
4.38–413.2) vs 57.1 pg/mL (0.79–354.9), respectively, P =
0.02] were found to be significantly higher in the group
exposed to lead compared to the control group.
Transthoracic echocardiographic measurements of
the groups are shown in Table 2. Left ventricular ejection
fractions, left ventricular end-diastolic diameters, and
left ventricular end-systolic diameters were similar and
normal in the two groups. In terms of diastolic functions
parameters, no statistically significant difference was
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Table 1. Baseline demographic, clinical, laboratory, and serologic data of the lead-exposed and control groups.
Characteristics

Lead-exposed group
(n = 51)

Control group
(n = 54)

p

Age (years)

34.4 ± 7.2

33.0 ± 7.9

0.347

Systolic blood pressure (mmHg)

123.6 ± 14.2

121.9 ± 13.8

0.535

Diastolic blood pressure (mmHg)

76.5 ± 8.2

74.1 ± 7.8

0.127

Body mass index (kg/m2)

21.9 ± 2.1

22.0 ± 2.3

0.751

Hemoglobin (g/dL)

15.5 ± 1.24

15.7 ± 1.13

0.492

White blood cell count (/µL)

7343 ± 1649

7117 ± 1711

0.986

Neutrophil count (/µL)

4085 ± 1352

4089 ± 1179

0.551

Lymphocyte count (/µL)

2414 ± 750

2332 ± 661

0.246

Platelet count (/µL)

227880 ± 46144

229090 ± 44637

0.892

Fasting blood glucose (mg/dL)

91.8 ± 8.8

89.3 ± 9.4

0.166

Total cholesterol (mg/dL)

174.2 ± 35.8

186.3 ± 37.2

0.092

Low-density lipoprotein (mg/dL)

108.8 ± 30.8

116.1 ± 25.8

0.193

High-density lipoprotein (mg/dL)

45.2 ± 9.7

47.7 ± 9.3

0.169

Triglyceride (mg/dL)

142.0 ± 77.2

160.5 ± 60.3

0.177

Creatinine (mg/dL)

0.81 ± 0.11

0.85 ± 0.11

0.097

Alanine aminotransferase (U/L)

23.2 ± 11.0

23.4 ± 7.9

0.903

Aspartate aminotransferase (U/L)

20.1 ± 6.2

21.3 ± 7.6

0.375

Thyroid stimulating hormone (µIU/mL)

1.35 ± 0.79

1.54 ± 0.90

0.234

Triiodothyronine (pg/mL)

2.96 ± 0.50

2.81 ± 0.45

0.115

Thyroxine (ng/dL)

1.07 ± 0.21

1.16 ± 0.28

0.068

Erythrocyte sedimentation rate (mm/h)

6 [1–30]

9 [1–22]

0.148

Serum endocan level (pg/mL)

67 [4.38–413.2]

57.1 [0.79–354.9]

0.020

Blood lead level (µg/dL)

32 [13.3–78]

1.5 [0.6–3.1]

<0.001

Table 2. Transthoracic echocardiographic parameters of the groups.

Characteristics

Lead-exposed group
(n = 51)

Control group
(n = 54)

p

Left ventricular end diastolic diameter (mm)

46.4 ± 2.3

46.1 ± 3.0

0.643

Left ventricular end systolic diameter (mm)

28.6 ± 2.8

28.5 ± 3.0

0.823

Left ventricular ejection fraction (%)

64.8 ± 3.0

64.4 ± 2.8

0.426

E wave (cm/s)

104.1 ± 9.5

108.2 ± 10.3

0.030

A wave (cm/s)

100.1 ± 15.2

95.8 ± 14.1

0.138

E/A ratio

1.06 ± 0.16

1.15 ± 0.23

0.011

E’ wave (cm/s)

10.9 ± 1.9

12.3 ± 1.6

0.001

E/E’ ratio

9.8 ± 1.8

8.9 ± 1.2

0.006

Isovolumic relaxation time (ms)

82.3 ± 7.7

82.0 ± 7.3

0.970

Deceleration time (ms)

183.2 ± 15.2

182.0 ± 14.5

0.686

32.3 ± 3.5

30.9 ± 3.0

0.035

Left atrial volume index (mL/m )
2
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found between the groups regarding A wave, isovolumic
relaxation time, and deceleration time. However, E wave
(104.1 ± 9.5 cm/s vs 108.2 ± 10.3 cm/s, P = 0.03), E/A ratio
(1.06 ± 0.16 vs 1.15 ± 0.23, P = 0.011) and E’ wave (10.9 ±
1.9 cm/s vs 12.3 ± 1.6 cm/s, P = 0.001) were found to be
lower in the lead-exposed group than that of controls. On
the other hand, E/E’ ratio (9.8 ± 1.8 vs 8.9 ± 1.2, P = 0.006)
and left atrial volume index (32.3 ± 3.5 mL/m2 vs 30.9 ±
3.0 mL/m2, P = 0.035) were found to be higher in the leadexposed group than that in the control group.
In correlation analysis in the lead-exposed group
(Table 3), E wave (r = 0.339, P = 0.015 and r = 0.382, P =
0.006, respectively) and E/E’ ratio (r = 0.387, P = 0.005,
Figure 1A and r = 0.393, P = 0.004, Figure 1B, respectively)
were to be significantly correlated with both blood lead
levels and serum endocan level. Serum endocan level was
negatively correlated with E’ wave (r = −0.301, P = 0.032,
Figure 2) and positively correlated with left atrial volume
index (r = 0.379, P = 0.007, Figure 3). Additionally, serum
endocan level showed a positive correlation with blood
lead levels (r = 0.404, P = 0.003, Figure 4) While A wave,
E/A ratio, isovolumic relaxation time, and deceleration
time were not found to be correlated with blood lead and
serum endocan levels.
In multivariate stepwise linear regression analysis in
the lead-exposed group (Table 4), serum endocan level
was found to be an independent risk factor for increased
E/E’ ratio (β = 0.704, P = 0.002) and left atrial volume
index (β = 1.158, P = 0.011). Additionally, a higher level of
lead in blood was found to be an independent risk factor
for increased E wave (β = 8.004, P = 0.022).
4. Discussion
In the present study, diastolic functions on
echocardiography were evaluated. In the lead-exposed

workers, compared to control subjects, while E/E’ ratio and
left atrial volume index were found to be higher, E wave,
E/A ratio, and E’ wave were found to be lower. Moreover,
serum endocan levels as a novel biomarker for vascular
inflammation and endothelial dysfunction were increased
in these workers. Additionally, significant correlations
were found between diastolic parameters, serum endocan
and blood lead levels.
The leading negative effects of lead on the
cardiovascular system show themselves in blood pressure
profile (2) and the atherosclerotic process in arterial
system (12). However, occupational exposure to lead
may also contribute to impairment of left ventricular
diastolic dysfunction but there are only a few studies in
which echocardiographic examination was performed.
Poreba et al. (3) demonstrated worsened systolic and
diastolic functions on echocardiography in patients with
occupational exposure to lead. Deceleration time and
E/E’ ratio in these patients were observed to be higher
compared to the control subjects, whereas the E/A ratio
and E’ wave were lower. Similarly, in the present study,
E/E’ ratio was also found to be higher and E’ wave and
E/A ratio were also found to be lower in lead-exposed
workers. In contrast, left atrial volume index was also
found to be higher in lead-exposed workers in the present
study and deceleration time and systolic functions did not
show a significant difference between the lead-exposed
workers and the control subjects. Additionally, high blood
zinc protoporphyrin concentration, which is an indicator
of lead exposure, was demonstrated to be a negatively
independent risk factor for E’ wave in the above-mentioned
study. In the present study, blood lead levels were found to
be independent risk factors for E wave.
It has been suggested that mechanisms involved
in ventricular diastolic dysfunction and endothelial

Table 3. Correlation analysis results between blood lead level, endocan level, and echocardiographic
parameters of diastolic functions in the lead-exposed workers.
Blood lead level
(µg/dL)

Serum endocan level
(pg/mL)

r

P

r

P

E wave (cm/s)

0.339

0.015

0.382

0.006

A wave (cm/s)

0.258

0.061

0.097

0.497

E/A ratio

−0.087

0.545

0.092

0.519

E’ wave (cm/s)

−0.251

0.076

−0.301

0.032

E/E’ ratio

0.387

0.005

0.393

0.004

Isovolumic relaxation time (ms)

−0.024

0.866

−0.033

0.819

Deceleration time (ms)

−0.182

0.201

0.014

0.925

0.0190

0.181

0.379

0.007

Characteristics

Left atrial volume index (mL/m )
2

69

KARA et al. / Turk J Med Sci

Figure 1. Graphics of correlation between E/E’ ratio and (A) blood lead level and (B) serum endocan level. Solid lines represent the
correlation slope, dotted lines represent 95% confidence intervals.

Figure 2. Graphic of correlation between E’ wave and serum
endocan level. Solid line represents the correlation slope, dotted
lines represent 95% confidence intervals.

Figure 3. Graphic of correlation between left atrial volume index
and serum endocan level. Solid line represents the correlation
slope, dotted lines represent 95% confidence intervals.

dysfunction might be similar (13). Increased oxidative
stress, decreased nitric oxide synthesis, imbalance
between vasomotor/vasodilator substances and excessive
sympathetic activity have been implicated the same
mechanisms involved in development of both endothelial
dysfunction and left ventricular diastolic dysfunction (14–
16). Ma et al. suggested that endothelial dysfunction was
related to left ventricular diastolic dysfunction in patients
with coronary heart disease (13). Elesber et al. showed
that coronary endothelial dysfunction was independently

associated with impaired relaxation in patients with normal
ejection fraction in the absence of occlusive coronary artery
disease and heart failure (17). Additionally, beneficial
effects of angiotensin-converting enzyme inhibitors and
beta blockers on diastolic dysfunction and endothelial
dysfunction also suggest that there may be a similar
mechanism in the development of myocardial injury
and endothelial impairment (18,19). In the case of lead
exposure, tissue damage might be seen through similar
mechanisms (20). Lead exposure promotes oxidative
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Figure 4. Graphic of correlation between serum endocan level
and blood lead level. Solid line represents the correlation slope,
dotted lines represent 95% confidence intervals.

stress and inflammation, increases endothelin production
and vasoconstrictor prostaglandins, and reduces nitric
oxide availability and vasodilator prostaglandins (4).
Thus, endothelial dysfunction may play a central role
in the relationship between lead exposure and diastolic
dysfunction (13).
Endocan was increased by many inflammatory
diseases and used as a biomarker for ongoing vascular
inflammation and endothelial dysfunction. Increased

serum endocan levels were observed in various clinical
settings characterized by endothelial dysfunction such
as hypertension (21), obstructive coronary artery disease
(22), acute coronary syndrome (9,23), and diabetes
mellitus (24, 25). In the present study, serum endocan level
was analyzed in the case of lead exposure, and endothelial
dysfunction as main link between lead exposure and
diastolic dysfunction has been evaluated by serum
endocan level for the first time. Serum endocan levels were
demonstrated to be higher and independent risk factors
for increased E/E’ ratio and left atrial volume index in the
lead-exposed group. Furthermore, serum endocan and
blood lead levels showed strong correlation in the leadexposed workers. It may be due to having similar effects
on the same milieu. Previous studies have shown that
lead reduces endothelial cell growth, impedes endothelial
repair, and promotes proinflammatory cytokines (4,26).
On the other hand, endocan has been implicated in
leukocyte–endothelium interaction and reported as a
marker for endothelial dysfunction (27).
In contrast with previous studies, the subjects of the
present study were normotensive and none of them had
any etiology which might result in diastolic dysfunction
since individuals with hypertension and structural
heart diseases were excluded. Results of the present
cross-sectional study suggest that lead exposure can be
assumed as a risk factor for changes in diastolic functions
regardless of blood pressure status and the presence of a
triangular relationship between lead exposure, endothelial
dysfunction evaluated by serum endocan level and
diastolic dysfunction.

Table 4. Multivariate stepwise linear regression analysis results for determination of predictors of E/E’ ratio,
E wave, and left atrial volume index in the lead-exposed workers.

β ± SE

95% Confidence interval

P

Lower

Upper

0.260

1.148

0.002

1.865

14.143

0.012

0.277

2.039

0.011

E/E’ Ratio
Serum endocan level (pg/mL)*

0.704 ± 0.221

R2 = 0.415, Adjusted R2 = 0.155, P = 0.002
E wave
Blood lead level (µg/dL)*

8.004 ± 3.055

R = 0.351, Adjusted R = 0.105, P = 0.012
2

2

Left atrial volume index
Serum endocan level (pg/mL)*

1.158 ± 0.439

R2 = 0.353, Adjusted R2 = 0.107, P = 0.011
β: Regression coefficients; SE: Standard error; R: Model fit. * Logaritmic transformation was applied to blood
lead level and serum endocan level in order to obtain normal distribution.
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4.1. Limitations of the study
Lead accumulates almost entirely in bone. In the present
study, only blood lead levels were analyzed. The workers
were evaluated with regard to their “lead exposure”
independent of their blood lead levels, so there was no cutoff value for blood lead concentration. Study groups were
extremely homogeneous due to tight exclusion criteria that
might cause to reduce representing real-world conditions.
In addition, workplace testing was not analyzed. Finally,
this study is cross-sectional in design and subjects were
not followed up in terms of cardiovascular end-points.

These limitations make it so hard to speculate long-term
cardiovascular complications. The findings of this study
will need confirmation with larger studies.
Impairment
in
diastolic
parameters
on
echocardiography may be seen in lead-exposed
individuals and serum endocan level may be a useful
marker for monitoring the development of cardiovascular
complications in the case of lead exposure even in the
early course of involvement. Other endothelial-dependent
cardiovascular complications in lead exposure are needed
to be studied.
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